Protein-based vaccine
Date: 14 August 2021 Tags: MiscellaneousIssue
Nanoparticles that mimic SARS-CoV-2 were used by researchers to immunize mice against the viral disease.
Details
-
Researchers made use of receptor binding domain (RBD) antigen to generate an anti-body response in the mice.
-
Nanoparticles were made similar to SARS CoV-2 and were implanted with many RBDs. They were then injected into mice.
-
Along with this decorated nanoparticles, researchers inserted separate nanoparticles containing adjuvant in form of separate doses.
-
Another group of mice were immunized with the help of RBD encapsulated polymersomes to compare with the nanoparticles.
-
High levels of RBD specific antibodies were generated in the bodies of the mice but neutralizing antibodies were produced in mice given surface decorated nanoparticles.
RBD
-
Receptor Binding Domain (RBD) can be considered as a critical part of viral protein that makes contact with the cell and allows entry of viral DNA inside.
-
The RBD is located near the spike protein and is the primary target of drugs trying to prevent the virus from infecting healthy cells.
Nanoparticles
-
Nanoparticles are types of matter that ranges between the size of 1 to 100 nanometers. These particles have unique physical and chemical characteristics that are not visible to naked eye.
-
Due to their precision and non-corrosive nature, nanoparticles are particularly used in medical science, food packaging and electronics technology.